Advertisement
Letter to the Editors-in-Chief| Volume 223, P127-130, March 2023

Download started.

Ok

Additive effect of factor X on the structure and stability of activated factor VII-induced fibrin clot in hemophilic plasma with inhibitor

Published:January 23, 2023DOI:https://doi.org/10.1016/j.thromres.2023.01.020
Additive effect of factor X on the structure and stability of activated factor VII-induced fibrin clot in hemophilic plasma with inhibitor
Previous ArticleThe efficacy of the rituximab-containing rescue-regimen for severe hemophilia A inhibitor children who relapsed following successful immune tolerance induction with rituximab in China
      Replacing deficient factor (F) VIII or FIX is the most common treatment strategy for congenital hemophilia; however, repeated infusions can promote the formation of FVIII or FIX inhibitors. Importantly, the appearance of these inhibitors significantly reduces the hemostatic effect of regular FVIII or FIX replacement [
      • Fischer K.
      • Lewandowski D.
      • Marijke van den Berg H.
      • Janssen M.P.
      Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project.
      Haemophilia. 2012; 18: e241-e246https://doi.org/10.1111/j.1365-2516.2011.02687.x
      ]. Recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrates (APCC) are used for hemostatic management in patients having hemophilia with inhibitors (PHwI). Additionally, the plasma-derived FVIIa (pdFVIIa) and FX mixture (FVIIa/FX; Byclot®, KM Biologics Co., Ltd., Kumamoto, Japan) comprising FVIIa and FX in a weight ratio of 1:10 that enhanced the hemostatic effect of FVIIa was approved in Japan for the episodic and prophylactic treatment of patients with PHwI. The recommended doses of FVIIa/FX for hemostatic control ranged from 60 to 120 μg/kg (FVIIa concentration), and the plasma concentration (Cmax) of FVIIa and FX can increase to 1.2–1.8 μg/mL and 17.3–29.7 μg/mL, respectively [
      • Shirahata A.
      • Fukutake K.
      • Takamatsu J.
      • Shima M.
      • Hanabusa H.
      • Mugishima H.
      • Amano K.
      • Takedani H.
      • Tamashima S.
      • Matsushita T.
      • Tawa A.
      • Tanaka I.
      • Higasa S.
      • Kosaka Y.
      • Fujii T.
      • Sakai M.
      • Migita M.
      • Kawakami K.
      • Ohashi Y.
      • Saito H.
      A phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
      Haemophilia. 2013; 19: 853-860https://doi.org/10.1111/hae.12205
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Fischer K.
        • Lewandowski D.
        • Marijke van den Berg H.
        • Janssen M.P.
        Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project.
        Haemophilia. 2012; 18: e241-e246https://doi.org/10.1111/j.1365-2516.2011.02687.x
        View in Article
        • Shirahata A.
        • Fukutake K.
        • Takamatsu J.
        • Shima M.
        • Hanabusa H.
        • Mugishima H.
        • Amano K.
        • Takedani H.
        • Tamashima S.
        • Matsushita T.
        • Tawa A.
        • Tanaka I.
        • Higasa S.
        • Kosaka Y.
        • Fujii T.
        • Sakai M.
        • Migita M.
        • Kawakami K.
        • Ohashi Y.
        • Saito H.
        A phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
        Haemophilia. 2013; 19: 853-860https://doi.org/10.1111/hae.12205
        View in Article
        • Nakatomi Y.
        • Nakashima T.
        • Gokudan S.
        • Miyazaki H.
        • Tsuji M.
        • Hanada-Dateki T.
        • Araki T.
        • Tomokiyo K.
        • Hamamoto T.
        • Ogata Y.
        Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent.
        Thromb. Res. 2010; 125: 457-463https://doi.org/10.1016/j.thromres.2009.12.010
        View in Article
        • He S.
        • Cao H.
        • Antovic A.
        • Blombäck M.
        Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials.
        Blood Coagul. Fibrinolysis. 2005; 16: 61-67https://doi.org/10.1097/00001721-200501000-00010
        View in Article
        • Lisman T.
        • Mosnier L.O.
        • Lambert T.
        • Mauser-Bunschoten E.P.
        • Meijers J.C.
        • Nieuwenhuis H.K.
        • de Groot P.G.
        Inhibition of fibrinolysis by recombinant factor FVIIa in plasma from patients with severe hemophilia A.
        Blood. 2002; 99: 175-179https://doi.org/10.1182/blood.v99.1.175
        View in Article
        • He S.
        • Blombäck M.
        • Jacobsson Ekman G.
        • Hedner U.
        The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/J FIX.
        J. Thromb. Haemost. 2003; 1: 1215-1219https://doi.org/10.1046/j.1538-7836.2003.00242.x
        View in Article
        • Corrigan Jr., J.J.
        Oral bleeding in hemophilia: treatment with epsilon-aminocaproic acid in the management of dental extractions in the hemophiliacs.
        Am. J. Med. Sci. 1964; 248: 184-188https://doi.org/10.1097/00000441-196408000-00007
        View in Article
        • Wyseure T.
        • Cooke E.J.
        • Declerck P.J.
        • Behrendt N.
        • Meijers J.C.M.
        • von Drygalski A.
        • Mosnier L.O.
        Defective TAFI activation in hemophilia a mice is a major contributor to joint bleeding.
        Blood. 2018; 132: 1593-1603https://doi.org/10.1182/blood-2018-01-828434
        View in Article
        • Semeraro F.
        • Mancuso M.E.
        • Ammollo C.T.
        • Dirienzo L.
        • Vitulli A.
        • Santagostino E.
        • Tripodi A.
        • Colucci M.
        Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A.
        J. Thromb. Haemost. 2020; 18: 381-389https://doi.org/10.1111/jth.14656
        View in Article

      Article info

      Publication history

      Published online: January 23, 2023
      Accepted: January 19, 2023
      Received in revised form: January 11, 2023
      Received: October 31, 2022

      Identification

      DOI: https://doi.org/10.1016/j.thromres.2023.01.020

      Copyright

      © 2023 Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX